Innovation and CSR on Chinese SOEs: Adapting to COVID-19

Yan Wang, Yunlang Xie

2022

Abstract

In 2020, COVID-19 spread all over the world, seriously threatening human life and health and severely impacting economic development. Chinese pharmaceutical state-owned enterprise (SOE) Da An Gene quickly developed new products and helped meet huge demands for protective supplies. Its “R&D innovation and corporate social responsibility (CSR)” interactive mechanism formed in the course of long-term innovation and capital accumulation enabled it to seize opportunities brought by the epidemic. This study explores the path of how innovative SOEs created value through interaction of R&D innovation and CSR with case study against the background of COVID-19, and whether reform of state-owned capital regulatory system to inject market vitality into SOEs can effectively transform the interaction mechanism of R&D innovation and CSR into sustainable core corporate competitiveness.

Paper Citation

in Harvard Style

Wang Y. and Xie Y. (2022). Innovation and CSR on Chinese SOEs: Adapting to COVID-19. In Proceedings of the 3rd International Symposium on Water, Ecology and Environment - Volume 1: ISWEE; ISBN 978-989-758-639-2, SciTePress, pages 175-186. DOI: 10.5220/0011954200003536

in Bibtex Style

@conference{iswee22,
author={Yan Wang and Yunlang Xie},
title={Innovation and CSR on Chinese SOEs: Adapting to COVID-19},
booktitle={Proceedings of the 3rd International Symposium on Water, Ecology and Environment - Volume 1: ISWEE},
year={2022},
pages={175-186},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0011954200003536},
isbn={978-989-758-639-2},
}

in EndNote Style

TY - CONF

JO - Proceedings of the 3rd International Symposium on Water, Ecology and Environment - Volume 1: ISWEE
TI - Innovation and CSR on Chinese SOEs: Adapting to COVID-19
SN - 978-989-758-639-2
AU - Wang Y.
AU - Xie Y.
PY - 2022
SP - 175
EP - 186
DO - 10.5220/0011954200003536
PB - SciTePress